Business Wire

Gramercy Funds Management Announces Close of Gramercy Capital Solutions Fund III

Share

Gramercy Funds Management LLC (“Gramercy”) a $6 billion global emerging markets investment manager, today announced the final close of its Gramercy Capital Solutions Fund III (“GCSF III” or the “Fund”), with $685 million in limited partner commitments to the Fund and an additional $75 million in co-investments to date. This combined raise of $760 million in the strategy represents a 28% increase from the June 2022 closing of the firm’s second fund (GCSF II) which closed with $592 million. The inaugural fund (GCSF I) closed in 2017 with commitments of $312 million. Virtually all the limited partners from GCSF I and GCSF II committed capital to GCSF III.

The Capital Solutions strategy is anchored by a dedicated 12-member team that has been working together for more than seven years. The team, led by Gustavo Ferraro as Senior Portfolio Manager, averages more than 20 years of experience in the field. The senior team is composed of Javier Ledesma-Arocena, Portfolio Manager, as well as Gian Marco Maltoni, Tomas Serantes, Lisandro Muller and Felipe Alonso. Headquartered in Greenwich, CT, the team is located throughout our investment region with offices in Argentina, Mexico and Miami, and is supported by our lending platforms located in Brazil, Colombia, Peru, Mexico and Turkey.

The Fund invests in USD loans, mostly primary, across Latin America (~75%) and CEEMEA (~25%), with a highly diversified approach across industries, company types and sizes. Loans aim to deliver attractive mid-teens returns with robust downside protection. They are typically structured as highly covenanted, asset-backed, self-liquidating structures, with strong LTV ratios and cash flow control. The Capital Solutions Investment Committee underwriting focuses on downside protection to our investment thesis and collateral value. Asymmetric risk-return is sought from managed cash-flow and asset-based collateral packages, structured for enforcement utilizing the best available and proven structures within EM jurisdictions.

Limited partners in the Fund consist of both existing and new investors located in Europe, North America and South America, including insurance companies, public pension plans, investment managers and family offices.

Gustavo Ferraro said, “We are excited to announce the final close of GCSF III and thank our investors for their commitment to this strategy. We believe our proven multi-channel approach to sourcing including our unique lending platforms providing strong visibility and rapid, dependable capital deployment remains very attractive to investors.” Regarding the investment environment he further commented, “…we have an ability to access a multitude of borrowers and negotiate attractive terms for the Fund because they see our capital as transformational for their businesses and growth aspirations.”

“Gramercy’s differentiated, better approach to emerging markets continues to prove effective through market cycles, and we look forward to deploying this new capital,” said Robert Koenigsberger, Managing Partner and Chief Investment Officer of Gramercy. He added, “Gramercy is a longstanding leader in emerging markets with over 25 years of expertise and an extensive global footprint. We leverage the depth of experience and knowledge represented in our investment team to focus on the best opportunities in private credit and direct lending corporate markets.”

To date, Gramercy has deployed approximately $5 billion in capital in this strategy across over 100 investments. The firm is optimistic regarding the opportunity to deliver for their investors through 2025 and beyond.

About Gramercy Funds Management

Gramercy is a global emerging markets investment manager based in Greenwich, Connecticut with offices in London, Buenos Aires, Miami, West Palm Beach and Mexico City, and dedicated lending platforms in Mexico, Turkey, Peru, Pan-Africa, Brazil, and Colombia. The $6-plus billion firm, founded in 1998, seeks to provide investors with a better approach to emerging markets, delivering attractive risk-adjusted returns supported by a transparent and robust institutional platform. Gramercy offers alternative and long-only strategies across emerging markets asset classes, including multi-asset, private credit, public credit, and special situations. Gramercy’s mission is to positively impact the well-being of our clients, portfolio investments and team members. Gramercy is a Registered Investment Adviser with the US Securities and Exchange Commission (SEC), a Signatory of the Principles for Responsible Investment (PRI), a Signatory to the Net Zero Asset Managers initiative (NZAMI) and a Supporter of the Task Force on Climate-Related Financial Disclosures (TCFD). Gramercy Ltd, an affiliate, is registered with the UK Financial Conduct Authority (FCA). For more information, visit www.gramercy.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241118827551/en/

Contacts

Media Contacts

Steve Bruce / Keely Gispan
ASC Advisors
(203) 992-1320
sbruce@ascadvisors.com / kgispan@ascadvisors.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i

Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release

Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d

The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release

Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release

4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release

Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye